@article{UBHD-68333858,
  author={Chekerov, Radoslav and Wischnik, Arthur},
  title={Treosulfan in the treatment of advanced ovarian cancer},
  subtitle={results of a German multicenter non-interventional study},
  year={2015},
  pages={6869-6875},
  language={eng},
  issn={1791-7530},
  volume={35},
  number={12},
  note={Gesehen am 29.11.2018},
  journal={Anticancer research},
}
@article{UBHD-68463612,
  author={Jacobs, Volker Rudolf and Wischnik, Arthur},
  title={Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine},
  subtitle={Results of a prospective multi-center study at certified breast centers},
  year={2016},
  pages={208-212},
  language={eng},
  issn={1532-3080},
  volume={29},
  note={Gesehen am 04.12.2019 ; Available online 23 June 2016},
  journal={The breast},
  doi={10.1016/j.breast.2016.06.014},
}
@article{UBHD-67778113,
  author={Jacobs, Volker Rudolf and Wischnik, Arthur},
  title={Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer},
  year={2013},
  pages={436-443},
  language={eng},
  issn={1532-3080},
  volume={22},
  number={4},
  note={Gesehen am: 24.02.2015},
  journal={The breast},
  doi={10.1016/j.breast.2013.04.009},
}
@article{UBHD-68450504,
  author={Janni, Wolfgang and Wischnik, Arthur},
  title={Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer},
  subtitle={final survival analysis of the ADEBAR study},
  year={2016},
  pages={863-871},
  language={eng},
  issn={1532-1827},
  volume={114},
  number={8},
  note={Gesehen am 05.11.2019},
  journal={British journal of cancer},
  doi={10.1038/bjc.2016.82},
}
@article{UBHD-68467668,
  author={Schwentner, Lukas Paul and Wischnik, Arthur},
  title={Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer},
  subtitle={results from the prospective multi-center randomized ADEBAR trial},
  year={2016},
  pages={69-77},
  language={eng},
  issn={1532-3080},
  volume={27},
  note={Gesehen am 13.12.2019},
  journal={The breast},
  doi={10.1016/j.breast.2016.03.003},
}